Artwork

Content provided by Vox Media Podcast Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Vox Media Podcast Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

A new era of cannabis research

38:04
 
Share
 

Manage episode 417107340 series 2486193
Content provided by Vox Media Podcast Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Vox Media Podcast Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Last week, the US Drug Enforcement Administration announced a move to reclassify marijuana as a Schedule III drug, after the Biden administration requested a review in late 2022. For decades, cannabis has been classified as Schedule I alongside drugs like heroin and LSD—and research on its effects and medical use has been limited. While rescheduling could lead to more clinical research on marijuana, the future is currently hazy. Today on The Weeds: what rescheduling cannabis means for medical research, and why it still might not be enough to push past the barriers that still exist.

Read More:

Marijuana could be classified as a lower-risk drug. Here’s what that means. - Vox

What marijuana reclassification means for the United States

Submit your policy questions!

We want to know what you’re curious about.

Credits:

Jonquilyn Hill, host

Sofi LaLonde, producer

Cristian Ayala, engineer

A.M. Hall, editorial director of talk podcasts

Want to support The Weeds? Please consider making a donation to Vox: bit.ly/givepodcasts

Please take a second to help us learn more about you! vox.com/podcastsurvey

Learn more about your ad choices. Visit podcastchoices.com/adchoices

  continue reading

724 episodes

Artwork

A new era of cannabis research

The Weeds

1,527 subscribers

published

iconShare
 
Manage episode 417107340 series 2486193
Content provided by Vox Media Podcast Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Vox Media Podcast Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Last week, the US Drug Enforcement Administration announced a move to reclassify marijuana as a Schedule III drug, after the Biden administration requested a review in late 2022. For decades, cannabis has been classified as Schedule I alongside drugs like heroin and LSD—and research on its effects and medical use has been limited. While rescheduling could lead to more clinical research on marijuana, the future is currently hazy. Today on The Weeds: what rescheduling cannabis means for medical research, and why it still might not be enough to push past the barriers that still exist.

Read More:

Marijuana could be classified as a lower-risk drug. Here’s what that means. - Vox

What marijuana reclassification means for the United States

Submit your policy questions!

We want to know what you’re curious about.

Credits:

Jonquilyn Hill, host

Sofi LaLonde, producer

Cristian Ayala, engineer

A.M. Hall, editorial director of talk podcasts

Want to support The Weeds? Please consider making a donation to Vox: bit.ly/givepodcasts

Please take a second to help us learn more about you! vox.com/podcastsurvey

Learn more about your ad choices. Visit podcastchoices.com/adchoices

  continue reading

724 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide